Pol Boudes, MD

Examiner
DISC Type : cs

Chief Medical Officer at Rectify Pharmaceuticals, Inc.

Pennington, New Jersey, United States

Overview

Dr. Pol Boudes is the Chief Medical Officer at Rectify Pharmaceuticals, bringing over 30 years of experience as a senior physician in the pharma and biotech industry. Specializing in Endocrinology and Metabolic Diseases, he has held numerous CMO roles and contributed to multiple new drug registrations. He earned his M. D. from the University of Aix-Marseille.

His passion is centered on bringing innovative, life-changing therapies to patients. This is reflected in his interest in exploring novel medical technologies, including the use of AI to improve the reading of tissue biopsies, and new therapeutic approaches for chronic liver, kidney, and rare genetic diseases, which he follows closely.

He was part of the team at Roche that discovered protease inhibitors, drugs that completely transformed the lives of patients with HIV.

Personality Overview

Unexpressive

Overcautious

Late Adopter

They are heavily focused on quality and prefer doing things the right way, even if it takes time.  The only way to convince them is by showing them examples and ample proof. They do not like taking risks at all and go for proven options in the end.

Topics They Care About

Orphan Drug Development
His career has a strong emphasis on developing treatments for orphan, rare, and neglected diseases, including pioneering chaperone therapies for lysosomal storage disorders at Amicus Therapeutics.
Hepatobiliary Diseases
He has extensive experience leading clinical programs for liver diseases like NASH cirrhosis and primary biliary cholangitis at Galectin and CymaBay, and it remains a focus at Rectify.
ABC Transporters
His current role at Rectify Pharmaceuticals is focused on developing therapeutics that restore ABC transporter function to address the underlying cause of serious genetic diseases.

Media Appearances

Pol has no verified media appearances

Work History

8-2024
Chief Medical Officer at Rectify Pharmaceuticals, Inc.
1-2020
Board Member at Protalix Biotherapeutics (NYSE: PLX).
10-2013
Chief Medical Officer. International consultant Medical Affairs and Drug Development at Independent Chief Medical Officer
3-2020 - 8-2024
Chief Medical Officer at Galectin Therapeutics (NASDAQ: GALT)
4-2014 - 10-2019
Chief Medical Officer at Cymabay Therapeutics

Education

Doctor of Medicine (M.D.) from University of Aix-Marseille

More Information

Social Presence :

Prographics :

Exp : 12 Location : Pennington, New Jersey, United States Job Level : Leadership Designation : Chief Medical Officer at Rectify Pharmaceuticals, Inc.
URL has been copied!

Insights For Selling To Pol

During A Call Or A Meeting

DO's

  • Ask them which other stakeholders would be important for this purchase decision
  • Expect them to be vague in response to your questions, ask firmly and pointedly
  • Be firm in your communication and stay in control

DONT's

  • Don't push them too hard to make fast decisions, give them time
  • Don't use phrases like 'do not worry', 'i promise' etc.
  • Don't rely on relationship building even if they act pleasantly

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with Pol is

  • Adoption by others is very important to them, followed by confidence in ROI.
  • Will you ever get a clear answer from Pol

  • Often, they don't say no, or keep going about it in circles.

Insights For Deal Planning

    How fast (or slow) will Pol move?

  • They don't like to hasten, so their speed of decision-making may be slow.
  • Can Pol take some risk or not?

  • They have little willingness to take risks, and prefer making calculated decisions.

You And Pol

Personality Compatibility


More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.